Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD123/anti-CD3 bispecific DART molecule MGD024

An Fc-bearing, bispecific antibody-like protein directed against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/anti-CD3 bispecific DART molecule MGD024 simultaneously binds to both CD123-expressing cancer cells and CD3-expressing T cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain prolongs the half-life of the agent, and a reduced affinity of CD3-binding results in less cytokine release.
Synonym:anti-CD123/CD3 bispecific DART molecule MGD024
CD123 x CD3 bispecific DART molecule MGD024
dual-affinity re-targeting protein MGD024
Code name:MGD 024
MGD-024
MGD024
Search NCI's Drug Dictionary